Therefore, the objective of our pilot study was to determine if patients with acromegaly and modest IGF1 elevations (IGF1 levels 1 to 1.3x ULN) would benefit from stricter normalization of IGF1 with addition or dose escalation of PEGV therapy. The gene discussed is IGF1; the disease is acromegaly.